S&E lead within Takeda's Center for External Innovation group supporting business development engagements for the Rare Genetics & Hematology therapeutic area and the Global Gene Therapy organization.

Provide strategic guidance to the Rare Disease Drug Discovery Unit (DDU) on platforms and therapies to treat rare metabolic disorders, and deliver a pipeline of highly differentiated development candidates using the combined capabilities of our internal research teams with newly formed external partnerships.

Led biology groups and multi-functional teams for lysosomal storage disease and metabolic target programs (enzyme replacement, enzyme inhibitors, enzyme activators, transporter inhibitor), small molecule modulators of fibrosis, and small molecule program for complement disorder. • Delivered research candidates into pre-clinical development. Authored internal development candidate nomination reports, and sections of FDA pre-IND briefing book and IND submissions

Managed multi-institute (Pfizer, MIT, MGH) bioengineering projects to design, develop, and implement tissue engineered models for the translational prediction of safety and therapeutic efficacy of liver fibrosis therapies.